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Abstract Temozolomide has been used as a standard
therapy for the treatment of newly diagnosed glioblastoma
multiforme since 2005. To assess the effectiveness of
temozolomide in routine clinical practice, we conducted an
observational study at Maastricht University Medical
Centre (MUMC). Data of patients receiving radiotherapy
and temozolomide between January 2005 and January 2008
were retrieved from a clinical database (radiochemotherapy
group), as were data of patients in a historical control group
from the period before 2005 treated with radiotherapy only
(radiotherapy group). The primary endpoint was overall
survival. A total of 125 patients with GBM were selected to
form the study cohort. Median survival beneﬁt was
4 months: the median overall survival was 12 months
(95% CI, 9.7–14.3) in the group with radiochemotherapy
with temozolomide, versus 8 months (95% CI, 5.3–10.7) in
the group with only radiotherapy. Progression-free survival
was 7 months (95% CI, 5.5–8.5) in the radiochemotherapy
group and 4 months (95% CI, 2.9-5.1) in the group with
only radiotherapy. The two-year survival rate was 18%
with radiochemotherapy with temozolomide against 4%
with radiotherapy alone. Concomitant treatment with
radiotherapy and temozolomide followed by adjuvant
temozolomide resulted in grade III or IV haematological
toxic effects in 9% of patients. The addition of temozolo-
mide to radiotherapy in routine clinical practice for newly
diagnosed glioblastoma resulted in a clinically meaningful
survival beneﬁt with minimal haematological toxicity,
which conﬁrms the experience of previous trials and jus-
tiﬁes the continued use of temozolomide in routine clinical
practice.
Keywords Temozolomide  Glioblastoma multiforme 
Survival  Routine clinical practice  Radiotherapy
Introduction
Gliomas represent about half of all histologically veriﬁed
primary CNS cancers among adults [1]. Glioblastoma
multiforme (GBM), grade IV glioma, is the most frequent
and most aggressive type of malignant brain tumour. The
most characteristic features of GBM are necrosis and
endothelial proliferation [2]. Despite the best available
treatment, the clinical course is fatal, with a median
survival of less than one year [3]. Factors that are prog-
nostic for survival, apart from treatment modalities, are
patient age, performance status and degree of surgical
resection [1, 3–13]. When a high grade glioma is sus-
pected, maximal resection of the tumour is aimed for, on
condition that neurological functions are spared. Such
cytoreductive surgery is of limited value without adjuvant
therapy. Until 2005, standard therapy consisted of surgical
resection, followed by radiotherapy, which has been
shown to prolong survival [14]. Unfortunately, the
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DOI 10.1007/s11060-009-9956-7addition of various chemotherapeutics only resulted in
marginal survival beneﬁts [15, 16]. Therefore, chemo-
therapy was not part of standard therapy for GBM in
Europe and was only administered in the context of
clinical trials. This changed after the publication of an
EORTC/NCIC study in 2005, in which Stupp et al.
demonstrated improved survival in patients with a histo-
logical diagnosis of glioblastoma multiforme, when con-
comitant temozolomide followed by adjuvant
temozolomide was added to the standard treatment [17].
Similar results were seen in a smaller phase II trial by
Athanassiou et al [18]. Temozolomide is an oral alkylat-
ing agent, with a lower toxicity proﬁle than most other
chemotherapeutic agents [19]. It can easily cross the
blood-brain barrier, so that cerebrospinal ﬂuid levels can
reach at least 20% of those observed in the plasma [20].
Since the publication of these studies, temozolomide has
been widely adopted as the new standard of care for
patients with newly diagnosed GBM.
The outcome of randomised controlled trials cannot be
directly applied without considering differences in patient
characteristics between the trial population and patient
populations in routine clinical practice. The objective of
the present study was to assess the effectiveness of tem-
ozolomide in addition to radiotherapy in patients with
newly diagnosed GBM in routine clinical practice. For this
purpose, we conducted an observational study at Maas-
tricht University Medical Centre (MUMC) among patients
receiving radiotherapy and temozolomide and a historical
control group of patients who were treated with radio-
therapy only.
Patients and methods
Study objectives
The primary endpoint in this study was overall survival
(OS), deﬁned as the time from the starting date of radio-
therapy to the date of death. Secondary endpoints were
progression-free survival (PFS), 2-year overall survival and
toxicity. PFS was deﬁned from the starting date of radio-
therapy to the date of tumour progression or death. The
exact date of death was acquired from a database held at
the General Registry Ofﬁce of the Dept. of Radiation
Oncology (MAASTRO Clinic). The safety and tolerability
of temozolomide were estimated in the radiotherapy plus
temozolomide group by assessing the haematological and
non-haematological toxicity data from medical records and
routine blood examinations. Although the National Cancer
Institute has updated its Common Toxicity Criteria into
version 3.0 (2006), we used version 2.0 to ensure better
comparability with previous trials.
Eligibility
Since 1991, the Neuro-Oncology Department of the
MUMC has been entering data on all neuro-oncological
patients who are discussed in its weekly neuro-oncology
meetings into a database. For the present study, we added
data on patients who had not been discussed in these neuro-
oncology meetings, but who had been registered in a
pathology database (PALGA) with a histological GBM
diagnosis. This allowed us to identify all patients aged 18
to 70 years who had a newly diagnosed and histologically
conﬁrmed supratentorial GBM according to the World
Health Organization classiﬁcation and who had been
referred to the MUMC between January 2000 and January
2008. Data of patients who received radiotherapy and
temozolomide between January 2005 and January 2008
were collected from this database (radiochemotherapy
group). Data of patients receiving radiotherapy only were
retrieved from the database for the period before 2005
(radiotherapy group). The subtypes of GBM, namely giant
cell and gliosarcoma, were included.
Patients with a secondary glioblastoma, based on a prior
histopathological diagnosis of a lower grade astrocytoma,
were excluded. In cases where the ﬁrst histopathological
diagnosis was glioblastoma, but the clinical history was
longer than one year, the pathologist was asked to do fur-
ther immunohistochemical examinations to conﬁrm or
exclude the diagnosis of primary glioblastoma. Patients
with gliomatosis cerebri were excluded, as well as patients
with prior chemotherapy.
Treatment
All patients had surgery before radiotherapy. The extent of
the surgery was deﬁned as biopsy, partial resection or
macroscopically complete resection and was determined
from the surgical report and postoperative imaging, if
performed. In the radiochemotherapy group, patients
received radiotherapy with concomitant temozolomide,
followed by adjuvant temozolomide, whereas the reference
group received radiotherapy only (same radiotherapy
treatment scheme with 30 fractions of 2 Gy to total dose of
60 Gy as used in the EORTC study by Stupp et al. [17]).
Chemotherapy consisted of temozolomide at a dose of
75 mg/m
2 per day, seven days a week for 42 consecutive
days during radiotherapy. After a break of four weeks,
patients received six cycles of adjuvant temozolomide at a
dose of 150 to 200 mg/m
2, on days 1 through 5, every
28 days. Prophylactic co-trimoxazol against Pneumocystis
carinii was given. Antiemetics, anticonvulsants and corti-
costeroids were prescribed if needed.
In case of disease progression, patients were assessed for
their performance status and were offered ‘salvage
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123therapy’, such as surgery, re-irradiation, second-line che-
motherapy and/or supportive care.
Statistical analysis
Overall and progression-free survival curves were plotted
using the method developed by Kaplan and Meier. The Cox
proportional hazards model was used to adjust the hazard
ratio for confounding and to improve the statistical efﬁ-
ciency. The prognostic factors tested were age, sex, WHO
performance status and extent of surgery, since these have
been reported in the literature as prognostic factors for
survival outcome [1, 3–13].
We corrected for age per decade rather than the binary
categories above or below 50 years, to obtain a more
accurate measure of this variable. P-values lower than 0.05
were considered to be statistically signiﬁcant. Statistical
analysis was performed using the Statistical Package for
the Social Sciences 15.0 (SPSS, Inc., Chicago, IL).
Results
Patient characteristics
One hundred and twenty-ﬁve patients with GBM were
selected to form the study cohort. Patient details are out-
lined in Table 1. Median age was 56 years. Male/female
ratio was 1.55. The initial complaints were motor symp-
toms in 34% of the patients, headache in 45%, epileptic
seizures in 33%, personality change in 12%, and speech
disorder in 26%. The radiochemotherapy group consisted
of 67 patients and the radiotherapy group of 58 patients.
The median time from diagnosis to start of treatment was
5.9 weeks in the radiotherapy group and 3.9 weeks in the
radiochemotherapy group. The baseline characteristics of
the patients were not balanced as regards sex, extent of
resection, corticosteroid use, giant cell or waiting time
between diagnosis and the start of treatment.
Treatment
Median received radiation dose was 60 Gy (range, 4–
60 Gy). Ten patients (8%) did not complete the entire
radiotherapy, reasons including disease progression and
death. Among the 67 patients who started radiochemo-
therapy, 93% completed the concomitant phase with both
radiotherapy and temozolomide. Of the 67 patients in the
radiochemotherapy group, 75% started the adjuvant ther-
apy with temozolomide after the 4-week break. Seventy
percent of the radiochemotherapy group completed
three cycles of temozolomide, and 40% had ultimately
completed six cycles (see Table 2). The main reason for
not completing concomitant and/or adjuvant temozolo-
mide therapy in our study was disease progression,
assessed by clinical deterioration and/or radiological
assessment. Five patients (7.5%) in the radiochemother-
apy group discontinued therapy because of haematologi-
cal toxicity effects.
Table 1 Patient characteristics
Characteristic Radiotherapy
(N = 58)
Radiochemotherapy
(N = 67)
Age (year)
Median 56 57
Range 33–70 25–70
Sex––no. (%)
Male 29 (50) 47 (70)
Female 29 (50) 20 (30)
WHO performance status, no. (%)
0 23 (40) 25 (37)
1 24 (41) 30 (45)
2 8 (14) 11 (16)
3 3 (5) 1 (2)
Extent of surgery, no. (%)
Biopsy 33 (57) 30 (45)
Partial 11 (19) 12 (18)
Macroscopically
complete resection
14 (24) 25 (37)
Time from diagnosis to treatment, wk
Median 5.9 3.9
Range 0.7-18 2-8.4
Corticosteroid therapy, no. (%)
Yes 39 (67) 46 (69)
No 5 (9) 20 (30)
Data missing 14 (24) 1 (2)
Subtype of glioblastoma, no. (%)
Giant cell 1 (2) 6 (9)
Table 2 Temozolomide compliance
Treatment episode % Completed
Week 3 RT concomitant 100.0
Week 5 RT concomitant 97.0
Total concomitant period 92.5
Cycle 1 74.6
Cycle 2 73.1
Cycle 3 70.1
Cycle 4 44.7
Cycle 5 43.2
Cycle 6 40.3
J Neurooncol (2010) 96:249–257 251
123Survival and progression
The follow-up ended on 8 July 2008. The unadjusted
hazard ratio for death in the radiochemotherapy group
compared to the radiotherapy group was 0.48 (95% CI,
0.32–0.72; P\0.001). Multivariate analysis, including all
considered covariates gave the same hazard ratio: 0.47
(95% CI, 0.29–0.73; P = 0.001). The Kaplan–Meier curve
showed a median overall survival of 12 months (95% CI,
5.3 to 10.7) in the radiochemotherapy group, versus
8 months (95% CI, 9.7–14.3) in the group with radiother-
apy only (Fig. 1 and Table 3). The estimated median sur-
vival beneﬁt was therefore 4 months.
The unadjusted hazard ratio for PFS of radiochemo-
therapy compared to the radiotherapy was 0.58 (95% CI,
0.39–0.85; P = 0.006). The adjusted hazard ratio, cor-
rected for all considered factors, was 0.59 (95% CI, 0.38–
0.91; P = 0.016). The median progression-free survival
was 7 months (95% CI, 5.5–8.5) with radiochemotherapy
and 4 months (95% CI, 2.9–5.1) with only radiotherapy
(Fig. 2, Table 3). The two-year survival rate was 18% in
the radiochemotherapy group and 4% in the group with
only radiotherapy.
The waiting time (medians 5.9 for radiotherapy and
3.9 weeks for radiochemotherapy) was also added to the
Cox Regression model. The adjusted hazard ratio for death
of radiotherapy plus temozolomide compared to radio-
therapy alone, then became 0.42 (95% CI, 0.24–0.73;
P = 0.002). This change of the HR was caused by a clear
positive association between waiting time and survival in
Fig. 1 Kaplan–Meier curves of overall survival: radiochemotherapy
versus radiotherapy only. P value = 0.000. Censored: Still alive at
end of study period 08-07-08
Table 3 Overall and
progression-free survival
Variable Radiotherapy (N = 47) Radiochemotherapy (N = 66)
Value (95% CI) Value (95% CI)
Median overall survival (months) 8.0 (5.3–10.7) 12.0 (9.7–14.3)
Overall survival (%)
At 6 months 57.4 78.8
At 12 months 23.4 46.8
At 24 months 4.3 18.2
Median progression-free survival (months) 4.0 (2.9–5.1) 7.0 (5.5–8.5)
Progression-free survival (%)
At 6 months 34.0 56.1
At 12 months 6.4 26.6
At 24 months 2.1 9.5
Fig. 2 Kaplan–Meier curves of progression-free survival: radioche-
motherapy versus radiotherapy only. P-value = 0.003. Censored:
Still alive at end of study period 08-07-08
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123the radiotherapy group as is shown in Fig. 3. This associ-
ation is probably due to patient selection. In the radio-
chemotherapy period (2005–2008), there was a weak
inverse association.
Subgroup analysis
Survival was analysed according to the prognostic factors.
Radiochemotherapy was associated with a signiﬁcant
improvement in median overall survival in nearly all sub-
groups of patients, with the exception of the relatively large
subgroup of patients who underwent biopsy only and the
patients with a WHO performance status 1 (whereas those
with the poorer performance status WHO 2 and 3 did show
a signiﬁcant improvement in median survival).
Comparison with EORTC/NCIC trial
To achieve the best possible comparison of the effect of
this new treatment in routine clinical practice and in the
EORTC/NCIC trial, we calculated what the effect of the
treatment in our setting would have been for the patients of
the EORTC/NCIC trial. To this end, we entered the mean
patient characteristics of their trial population (Table 4)
into our Cox regression model. The survival curve in Fig. 4
shows the effect of treatment on the survival of an average
patient in the EORTC trial. This patient would be expected
to survive for 10.0 months with radiotherapy and
14.2 months when temozolomide was added to the treat-
ment. An average patient in our routine clinical practice
cohort survived 9.0 months with radiotherapy and
12.9 months with radiochemotherapy (Fig. 5).
Toxicity
Detailed toxicity data were not recorded for the radio-
therapy group in the neurology treatment charts, whereas
temozolomide-related haematotoxicity was recorded for
each patient in the radiochemotherapy group. Six patients
(9%) had any type of grade III or IV haematological toxic
effect. In ﬁve of these cases chemotherapy was discontin-
ued. Anti-epileptic drugs were given to 41% of patients in
the radiotherapy group and 47% of patients in the radio-
chemotherapy group. Only 5% received the non-enzyme
inducing valproic acid.
Treatment after disease progression
At the moment of disease progression, four patients in both
treatment groups underwent a second surgery, seven
patients were re-irradiated, 16 patients received additional
cycles of temozolomide and four patients received second-
line chemotherapy other than temozolomide. In total, 17%
of patients in the radiochemotherapy group and 18% of
patients in the radiotherapy group received salvage che-
motherapy (see Table 5). Salvage chemotherapy consisted
of additional cycles of temozolomide in 67% of patients in
the radiochemotherapy group and 100% of patients in the
radiotherapy group.
Discussion
Since the publication of randomised trials in which patients
with newly diagnosed glioblastoma multiforme (GBM)
showed a prolonged survival when treated with both
radiotherapy and temozolomide, this chemotherapeutic
Fig. 3 Correlation between
waiting time and survival in
radiotherapy and
radiochemotherapy groups
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123agent has been implemented as the standard therapy. To
verify the value of this established treatment with tem-
ozolomide in routine clinical practice, we conducted an
observational study at the Maastricht University Medical
Centre, comparing survival in a cohort of patients receiving
radiochemotherapy with that in a historical control group
receiving radiotherapy only. Our study showed that radio-
chemotherapy is indeed also effective in routine clinical
Table 4 Patient
characteristics––comparison
with EORTC/NCIC trial
Characteristic Present study Stupp et al.
RT RT ? TMZ RT RT ? TMZ
Age (year)
Median 56 57 57 56
Sex (%)
Male 50 70 61 64
Female 50 30 39 36
WHO performance status (%)
04 0 3 7 38 39
14 1 4 5 49 47
21 4 1 6 12 13
35 2 00
Extent of surgery (%)
Biopsy 57 45 16 17
Partial 19 18 45 44
Macroscopically complete resection 24 37 40 39
Time from diagnosis to treatment––wk
Median 5.9 3.9 5.0 5.0
Corticosteroid therapy (%)
Yes 67 69 75 67
No 9 30 24 33
Data missing 24 2 \10
Subtype of glioblastoma (%)
Giant cell 2 9 ? ?
Fig. 4 Survival curve of an average patient of the EORTC/NCIC trial Fig. 5 Survival curve of an average patient of selected patients from
clinical practice
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123practice, although the effectiveness is somewhat different
from that in the published trials.
We found a median overall survival of 12.0 months in
the group with radiochemotherapy and 8.0 months in the
group with radiotherapy only. The median survival beneﬁt
in the present study was thus 4 months, which is lower than
the 5.7 months beneﬁt found by Athanassiou et al. but
higher than the 2.5 months median survival beneﬁt found
by Stupp et al. (Table 6). [17, 18] In the study by Ath-
anassiou et al. the dose of temozolomide during the con-
comitant phase was the same, but temozolomide was given
every two instead of four weeks during the adjuvant phase.
It remains unclear whether that is an explanation for the
higher survival beneﬁt in their study.
In our study, 40% of all patients in the radiochemo-
therapy group completed the concomitant and total adju-
vant treatments, which was slightly higher than the 36.6%
in the study by Stupp et al. while 61.4% of the patients in
the trial by Athanassiou et al. completed six cycles of
temozolomide. The difference in compliance between the
present study and the phase III trial by Stupp et al. can only
partially explain the larger median survival beneﬁt in our
study.
The decrease in waiting time with median times of 5.9
until 2005 and 3.9 in recent years is the consequence of a
more time-efﬁcient approach to patients with GBM intro-
duced in recent years. It has been reported that a delay until
the ﬁrst fraction of radiotherapy after surgery or after ﬁrst
consultation in the radiotherapy department results in a
clinically signiﬁcant reduction of survival for patients with
glioblastoma [21–24]. We investigated the correlation
between waiting time and survival and found a positive
association in the radiotherapy group, which seems to be
responsible for the stronger therapeutic effect (lower haz-
ard ratio) after correction for waiting time. This association
is probably caused by selection: patients assessed as ‘bet-
ter’ in terms of performance status had to wait longer for
treatment. Recently Blumenthal et al. also showed that
delaying initiation of radiotherapy did not show reduction
in survival, but a superior outcome instead [25]. These
comparable results may be based on the same kind of
patient selection for early treatment as was mentioned
before. The difference in waiting time between the two
cohorts could not explain the larger survival beneﬁt in the
present study compared to the EORTC/NCIC trial (median
waiting time being 5 weeks in both groups).
The fact that the median overall survival was shorter in
both groups in the present study than in the EORTC/NCIC
trial can at least partly be explained by a larger number of
patients being surgically treated with biopsy only. In our
study, 57% and 45% of the radiotherapy and radiochemo-
therapy groups, respectively, had a biopsy only, versus
16% and 17% in the EORTC/NCIC trial. Most studies have
shown a signiﬁcant survival advantage for patients under-
going a more extensive degree of resection [3, 5, 10, 12,
13]. Also one has to keep in mind that both our study and
EORTC/NCIC trial did not show a clear survival advantage
in the subgroup with patients undergoing biopsy [17].
Although we have corrected for the possible confound-
ing factors, the slightly worse results in our MUMC cohort
can also be the consequence of the well-known phenome-
non of selection bias from patient selection for clinical
trials.
Since a primary goal of therapy for patients with GBM
is improvement or maintenance of quality of life, delaying
disease progression by extending the progression-free
survival is very important. The present study demonstrated
that the addition of temozolomide to radiotherapy achieved
a prolongation of the median progression-free survival
from 4 months in the radiotherapy group to 7 months in the
radiochemotherapy group (Table 6).
Survival from progression, that is, the difference
between OS and PFS, was shorter in our study (4.0 and
5.0 months in the radiotherapy and radiochemotherapy
groups, respectively) than in the EORTC/NCIC trial (7.1
and 7.7 months). This may be caused by less salvage
treatment. In our study, only 17% of the radiotherapy group
and 18% of the radiochemotherapy group received salvage
chemotherapy, whereas in the EORTC/NCIC trial, 72% and
58%, respectively, received salvage chemotherapy after
Table 5 Salvage treatment
Type of treatment Radiotherapy
(N = 47)
Radiochemotherapy
(N = 66)
Second surgery, no. (%) 0 (0) 4 (6)
Re-irradiation, no. (%) 1 (2) 6 (9)
Chemotherapy, no. (%) 8 (17) 12 (18)
Temozolomide 8 (17) 8 (12)
Other than temozolomide 0 (0) 4 (6)
Table 6 Overall and progression-free survival––comparison with
trials
Variable Radiotherapy Radiochemotherapy
Median (95% CI) Median (95% CI)
Overall survival (months)
Present study 8.0 (5.5–10.5) 12.0 (9.7–14.3)
Stupp et al. 12.1 (11.2–13.0) 14.6 (13.2–16.8)
Athanassiou et al. 7.7 (5.3–9.2) 13.4 (9.6–17.1)
Progression-free survival (months)
Present study 4.0 (2.9–5.1) 7.0 (5.5–8.5)
Stupp et al. 5.0 (4.2–5.5) 6.9 (5.8–8.2)
Athanassiou et al. 5.2 (4.0–7.4) 10.8 (8.1–14.7)
J Neurooncol (2010) 96:249–257 255
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both treatment groups underwent repeat surgery, compared
to only 4% in our study. Re-irradiation was given to 6% of
patients in the present study (3% before 2005 and 9% since
2005). The number of patients receiving re-irradiation in the
EORTC/NCIC trial was not reported [17].
Apart from biopsy and waiting time, reported patient
characteristics of the randomised EORTC trial and our
study were quite similar (Table 4). By estimating the
treatment effect of the EORTC/NCIC trial population in
our setting from our Cox regression model (Fig. 4), we
showed that a quite similar survival beneﬁt would have
been accomplished as what was achieved in our study
population (4.2 instead of 3.9 months) and a higher sur-
vival of 10 months with radiotherapy and 14.2 months
with radiochemotherapy.
Among the 125 cases of glioblastoma multiforme
included in this study, only seven patients (5.6%) had giant
cell glioblastoma multiforme. Normally, giant cell GBM
(GC-GBM) constitutes approximately 5% of the cases of
glioblastoma multiforme, and GC-GBM is recognised as a
distinct clinicopathologic entity in the WHO 2007 classi-
ﬁcation [2, 26]. The difference in the prevalence of the
giant cell subtype between the two groups in our study
(Table 1) is remarkable: one patient in the radiotherapy
group and six in the radiochemotherapy group. This might
be a coincidence but it is more probable due to a change in
pathological analysis. Patients with giant cell GBM were
on average 16.5 years younger than those with non giant
cell GBM and macroscopically complete resection was
possible in 71% patients versus 29% in non giant cell,
probably contributing to a better survival [27]. Unfortu-
nately, the Stupp trial did not mention the number of
patients with giant cell subtype.
Our results demonstrate that temozolomide combined
with radiotherapy is an effective chemotherapeutic agent
for patients with primary glioblastoma multiforme in
clinical practice.
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